Gilead Sciences (GILD) Tops Q2 Earnings and Revenue Estimates

Core Insights - Gilead Sciences reported quarterly earnings of $2.01 per share, exceeding the Zacks Consensus Estimate of $1.95 per share, with an earnings surprise of +3.08% [1] - The company generated revenues of $7.08 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 1.95% and showing a year-over-year increase from $6.95 billion [2] - Gilead's stock has increased by approximately 19.4% year-to-date, outperforming the S&P 500's gain of 7.9% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $2.16, with expected revenues of $7.45 billion, and for the current fiscal year, the EPS estimate is $8.02 on revenues of $28.68 billion [7] - The estimate revisions trend for Gilead was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Gilead belongs, is currently ranked in the top 41% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]